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OBJECTIVES We carried out a complete screening of the SCN5A gene in 38 Japanese patients with Brugada
syndrome to investigate the genotype-phenotype relationship.
BACKGROUND The gene SCN5A encodes the pore-forming -subunit of voltage-gated cardiac sodium (Na)
channel, which plays an important role in heart excitation/contraction. Mutations of SCN5A
have been identified in 15% of patients with Brugada syndrome.
METHODS In 38 unrelated patients with clinically diagnosed Brugada syndrome, we screened for SCN5A
gene mutations using denaturing high-performance liquid chromatography and direct
sequencing, and conducted a functional assay for identified mutations using whole-cell
patch-clamp in heterologous expression system.
RESULTS Four heterozygous mutations were identified (T187I, D356N, K1578fs/52, and R1623X) in
4 of the 38 patients. All of them had bradyarrhythmic complications: three with sick sinus
syndrome (SSS) and the other (D356N) with paroxysmal complete atrioventricular block.
SCN5A-linked Brugada patients were associated with a higher incidence of bradyarrhythmia
(4 of 4) than non–SCN5A-linked Brugada patients (2 of 34). Families with T187I and
K1578fs/52 had widespread penetrance of SSS. Notably, the patient with K1578fs/52, who
had been diagnosed as having familial SSS without any clinical signs of Brugada syndrome,
showed a Brugada-type ST-segment elevation after intravenous administration of pilsicainide
and programmed electrical stimulation-induced ventricular tachycardia. All of the mutations
encoded non-functional Na channels, and thus were suggested to cause impulse propagation
defect underlying bradyarrhythmias.
CONCLUSIONS Our findings suggest that loss-of-function SCN5A mutations resulting in Brugada syndrome
are distinguished by profound bradyarrhythmias. (J Am Coll Cardiol 2005;46:2100–6)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.08.043© 2005 by the American College of Cardiology Foundation
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brugada syndrome is an inherited disorder, characterized by
udden death from ventricular tachyarrhythmias especially
uring sleep, ST-segment elevation in the right precordial
eads, and conduction slowing in the absence of structural
eart disease (1,2). In approximately 15% of Brugada
atients, mutations of the SCN5A gene, which encodes the
ore-forming -subunit of voltage-gated cardiac sodium
Na) channel, have been identified, and functional analyses
or some of these mutations revealed a loss-of-function type
odulation (3–6). Because Na current plays a key role in
eart excitation/contraction, functional changes in these
hannels can cause a variety of cardiac phenotypes. Interest-
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ccepted August 1, 2005.ngly, mutations of SCN5A have been reported to generate
everal types of disease entities distinct from Brugada syn-
rome: congenital type 3 long-QT syndrome (7), idiopathic
entricular fibrillation (VF) (8), progressive cardiac conduc-
ion defect (PCCD) (9), congenital sick sinus syndrome
SSS) (10), atrial fibrillation (11), and even overlap syn-
rome (12,13).
In this study, we carried out a complete screening of the
CN5A gene in 38 Japanese Brugada patients to investigate
he genotype-phenotype relationship.
ETHODS
tudy subjects. This study enrolled 38 clinically diagnosed
apanese Brugada syndrome patients (all were unrelated
robands). The protocol for genetic analysis was approved
y the institutional ethics committee and was performed
nder its guidelines. All patients provided an informed
onsent before the genetic analysis. The diagnosis of
rugada syndrome was based on the presence of ST-
egment elevation 2 mm in leads V1 through V3 at
aseline or after administration of intravenous Na chan-
el blockers (e.g., pilsicainide) (14). The presence of
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December 6, 2005:2100–6 Bradyarrhythmia in SCN5A-Linked Brugada Syndromeight ventricular cardiomyopathy was excluded by echo-
ardiography. We defined diagnosis of SSS as having a
ocumented sinus pause 3 s or chronic sinus bradycar-
ia with a heart rate 50 beats/min.
eoxyribonucleic acid isolation and mutation analysis. The
ethods of DNA isolation and mutation analysis were
escribed elsewhere (15). Genetic screening was performed
or SCN5A by denaturing high-performance liquid chroma-
ography (DHPLC) using a WAVE System Model 3500
Transgenomic, Omaha, Nebraska).
ite-directed mutagenesis and electrophysiology. With
egard to the novel SCN5A mutations we identified, site-
irected mutagenesis was employed to construct mutants
15). The human cell line HEK293 was transiently trans-
ected with either wild-type human cardiac Na channel 
ubunit (hH1) or mutant cDNA by the LipofectAMINE
ethod according to the manufacturer’s instructions (In-
itrogen, Carlsbad, California) in combination with a bicis-
ronic plasmid (pEGFP-IRES-h1) encoding enhanced
reen fluorescent protein and the human 1-subunit (h1)
o visually identify cells expressing heterologous h1.
Sodium currents were recorded 24 to 48 h after transfection
sing the whole-cell patch-clamp technique and analyzed, as
e previously described (15). Functional expression studies
ere performed on multiple independent recombinants.
ESULTS
utation analysis. Table 1 shows clinical characteristics of
8 patients with Brugada syndrome enrolled in this study
Abbreviations and Acronyms
AVB  atrioventricular block
DHPLC  denaturing high-performance liquid
chromatography
h1  human 1-subunit
PCCD  progressive cardiac conduction defect
SSS  sick sinus syndrome
VF  ventricular fibrillation
VT  ventricular tachycardia
able 1. Clinical Characteristics of the Probands (n  38)
en/women 35/3
ge (yrs) 47.4  17.0
amily history of SCD 8 (21.1%)
ymptomatic 20 (52.6%)
SS 5 (13.2%)
Af 10 (26.3%)
T or VF
Documented 9 (23.7%)
Induced 22/27 (81.5%)
CD implantation 23 (60.5%)
alues are mean  SD for age. Age represents the age at which diagnosis of Brugada
yndrome was made.
ICD implantable cardioverter-defibrillator; pAf paroxysmal atrial fibrillation;r
CD  sudden cardiac death; SSS  sick sinus syndrome; VF  ventricular
brillation; VT  ventricular tachycardia.35 men/3 women, 20 symptomatic/18 asymptomatic, mean
ge 47.4  17.0 years). A total of 35 probands were already
ocumented with Brugada-type ST-segment elevation at
est (19 symptomatic/16 asymptomatic). The others (three
robands) displayed ST-segment elevation after intravenous
dministration of pilsicainide. Of 18 asymptomatic Brugada
atients, 16 underwent programmed electrical stimulation
nd 15 of them displayed ventricular tachycardia (VT) or
F. Five patients were associated with SSS.
We identified four heterozygous SCN5A mutations in
our unrelated patients: T187I (c559t), D356N (g1066a),
1578fs/52 (4729 aa insertion), and R1623X (c4864t).
igure 1 shows the positions of identified mutations.
1578fs/52 is a frame-shift mutation resulting in early
runcation of the channel protein. R1623X is a nonsense
utation that changes an arginine for a stop codon. The
esults of DHPLC and DNA sequencing were presented in
igure 2. Three (T187I, D356N, K1578fs/52) were novel
nd the other (R1623X) was reported to cause congenital
SS in combination with T220I (10). None of these
utations was found in 110 normal control individuals (220
hromosomes). Consistent with a previous report (4), the
ncidence of SCN5A mutations in the Brugada syndrome
atients we studied was approximately 10% (4 of 38).
linical features. FAMILY K-115 (T187I). The proband, a
3-year-old man, in the family K-115 experienced syncope
n his febrile state, and VF was documented. His electro-
ardiogram (ECG) at rest displayed a typical Brugada
yndrome pattern (Fig. 3A, left). After the implantation of
cardioverter-defibrillator, he showed sinus bradyarrhyth-
ia with occasional ventricular pacing (second beat in Fig.
A, right), indicating the complication of SSS. His affected
other also suffered from SSS and underwent a pacemaker
mplantation (Fig. 4A).
AMILY K-54 (D356N). The proband, a 62-year-old man, in
he family K-54 had recurrent syncope at age 61. He
howed a coved-type ST-segment elevation in the right
recordial leads (Fig. 3B), and VF was induced when he
nderwent an electrophysiological study. During hospi-
alization, a complete atrioventricular block (AVB) was
igure 1. Topology of the voltage-gated sodium (Na) channel. Scheme of
he transmembrane topology of the cardiac Na channel illustrating the
ocation of four mutations found in our study. The cardiac Na channel
-subunit consists of four domains (DI through DIV), each containing six
ransmembrane-spanning segments.ecorded when he experienced faintness. He had no
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Bradyarrhythmia in SCN5A-Linked Brugada Syndrome December 6, 2005:2100–6amily history of lethal arrhythmia or sudden cardiac
eath (Fig. 4B). His family members refused genetic
xaminations.
AMILY K-202 (K1578FS/52). A 68-year-old man (III-6, Fig.
C) who had received a pacemaker (AAI pacing) due to SSS
t age 52 experienced repetitive syncope. His ECG on
dmission showed a severe sinus arrest because of pace-
aker pacing and sensing failure. Three members of his
amily (III-4, III-7, and IV-1) also suffered from SSS and
igure 2. Denaturing high-performance liquid chromatography (DHPLC
hrough D) DHPLC confirms abnormal migration patterns in the affecte
lectropherograms demonstrate mutations in each proband.eceived a pacemaker, and one affected brother (III-2) had 3rst-degree AVB. One of them, a younger sister (III-7) of
he proband, died suddenly even after the pacemaker im-
lantation. In order to assess the association with cardiac Na
hannelopathies, the proband underwent a pilsicainide chal-
enge test. Intravenous pilsicainide (30 mg) produced a
arked prolongation of the PQ interval (240 ms¡ 320 ms)
nd revealed a typical Brugada-type ST-segment elevation
n the right precordial leads (Fig. 3C, upper panels).
lectrophysiological study induced monomorphic VT (Fig.
alysis and deoxyribonucleic acid (DNA) sequencing. (Top panels of A
ividuals. (Bottom panels of A through D) Automated DNA sequencing) an
d indC, lower panel). Then he was diagnosed as having Brugada
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December 6, 2005:2100–6 Bradyarrhythmia in SCN5A-Linked Brugada Syndromeyndrome along with SSS and subsequently received an
mplantable cardioverter-defibrillator.
AMILY K-185 (R1623X). The proband was a 65-year-old man
ho experienced recurrent syncope due to sinus arrest for
5 s at age 61 years and received a pacemaker. At age 65
ears, he had faintness due to VF at night and was
uccessfully resuscitated by electric defibrillation. His ECG
howed a coved-type ST-segment elevation in the precor-
ial leads (Fig. 3D). His family members refused an ECG
nd genetic analyses.
unctional analysis of SCN5A T187I, D356N, K1578fs/52,
nd R1623X. We performed biophysical assays for the four
ovel mutations using a heterologous expression system in
igure 3. Electrocardiogram (ECG) recordings. (A through D) ECG re
rogrammed electrical stimulation (S1-S1/S1-S2/S2-S3/S3-S4  600/28
entricular tachycardia.EK293 cells. The protocol is given schematically in Figure n. Figure 5A illustrates representative whole-cell current
races from cells expressing wild-type (WT), T187I,
356N, K1578fs/52, or R1623X Na channels in the pres-
nce of the coexpressed h1. None of the mutants showed
n inward Na current, indicating that all of the mutations
ere non-functional. Reportedly, incubation with mexil-
tine rescued the reduced current density of a mutant Na
hannel (M1766L) (16). We, therefore, incubated trans-
ected cells in medium containing 500 mol/l mexiletine,
ut failed to rescue the expression of these mutants (data not
hown).
The four mutations were all heterozygous. To assess the
unctional interaction between WT and mutant Na chan-
gs (V1 through V3) obtained from the probands. (Bottom panel of C)
/240 [ms]) at the right ventricular outflow tract induced monomorphiccordin
0/260els, we coexpressed the same amount of both plasmids in
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Bradyarrhythmia in SCN5A-Linked Brugada Syndrome December 6, 2005:2100–6ombination with h1 in HEK293 cells. Figures 5B and 5C
how voltage-dependence of steady-state inactivation/
ctivation and the peak currents. None of the mutants
hanged channel open probability or current densities,
uggesting that the mutants have no dominant-negative
ffect on WT channels.
ISCUSSION
n this report, we identified four loss-of-function SCN5A
utations, T187I, D356N, K1578fs/52, and R1623X in 38
onsecutive, unrelated cases of Brugada syndrome in Japan.
ll four probands were complicated with bradyarrhythmia,
uch as SSS or AVB. None of these probands had additional
CN5A mutations, suggesting that this type of “loss-of-
unction” overlap syndrome (Brugada syndrome plus SSS/
VB) may result from a single SCN5A mutation; SSS was
ocumented in 5 of 38 Brugada patients (Table 1), and SCN5A
igure 4. (A through D) Pedigrees are shown. Circles represent female sub
iagonal bars indicate deceased family members. Members carrying the m
s given in the figure. AVB  atrioventricular block; BS  Brugada syndutations were found in more than half of these five patients n3 of 5), indicating that the patients with the overlap
yndrome had a high probability of SCN5A mutations.
In patients with Brugada syndrome, several dozen
CN5A mutations have been reported to date, and the
unctional analysis of these mutations revealed a “loss-of-
unction” type modulation of the -subunit of Na channels.
he severity of channel dysfunction can be variable in terms
f channel conductance or gating properties, depending on
he types of mutation. Importantly, as shown in Figure 5A,
ll of the mutations that we identified in the present study
ere entirely non-functional, and had no dominant-
egative effect on WT channels. This complete suppression of
a channel function may be associated with the profound
onduction disturbance, and thus bradyarrhythmic phenotypes.
The loss-of-function type mutations of SCN5A are re-
ortedly responsible for not only Brugada syndrome but also
CCD (9,17,18), congenital SSS (10), and overlap syn-
rome (Brugada syndrome plus atrial standstill or sinus
nd squares represent male subjects. The arrowhead indicates the proband.
ion are represented by solid circles or solid squares. Further explanation
PM  patients with a pacemaker; SSS  sick sinus syndrome.jects aode dysfunction) (19,20), supporting the concept that
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December 6, 2005:2100–6 Bradyarrhythmia in SCN5A-Linked Brugada Syndromerugada syndrome and its bradyarrhythmic complications
re caused by a single SCN5A mutation. The cellular
echanism for bradyarrhythmias is either a slowing of
acemaker activity or a reduction in impulse propagation.
he former seems to be unlikely, because the pacemaker
urrent in sinus nodal cells is largely regulated by calcium
nd potassium channels, with a minor contribution of Na
hannels (21,22). Sodium channels in the center of the
ouse sinus node consist of tetrodotoxin-sensitive brain-
ype -subunits, not tetrodotoxin-insensitive heart-type
igure 5. Biophysical assay. (A) Whole-cell current recordings of wild-type
ransient transfection in HEK293 cells in the presence of h1. Currents w
ncrements from a holding potential of 120 mV. No currents were det
nactivation and activation of mutant Na channels cotransfected with WT
T-hH1: h1  1:1:1). The curve was fit with the Boltzmann equation: I
a currents were elicited at 30 mV from a holding potential of 120 m-subunits encoded by Scn5a, a mouse homologue of sCN5A (23). In addition, however, Scn5a-coded Na chan-
els were recently reported to play a role in sinus node
acemaking in mice (24). Meanwhile, the latter scenario
ay be likely; a functional defect of the Na channel can
esult in a reduction of impulse propagation in the vicinity
f the sinus node. Indeed, Scn5a-coded Na channels were
istributed in the periphery of the mouse sinus node (24),
nd heterozygous Scn5a knockout mice showed a prolonga-
ion of the P wave as well as the PR interval, suggesting slow
onduction within the atria and atrioventricular conduction
) and mutant sodium (Na) channels. Sodium channels were expressed with
corded at various membrane potentials from 90 to 90 mV in 10-mV
in cells expressing each mutant. (B) Voltage dependence of steady-state
ant-hH1 [or pRcCMV as a control to adjust the total amount of DNA]:
 [1exp((V-V1/2)/k)
1]. (C) Current densities of mutant Na channels.
H1  human cardiac Na channel -subunit.(WT
ere re
ected
(mut
/Iystem (25). Furthermore, a failure in impulse conduction in
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Bradyarrhythmia in SCN5A-Linked Brugada Syndrome December 6, 2005:2100–6he adjacent atrial myocardium (exit block) is one of the
athophysiological bases of human SSS (26,27).
Benson et al. (10) recently reported a young man with
ongenital SSS who had compound heterozygous SCN5A
utations, T220I and R1623X. Three members of his
amily had R1623X alone, and showed only subclinical
CG abnormality (first-degree AVB). On the other hand,
ur R1623X case (K-185), despite the absence of additional
utations, demonstrated more prominent phenotypes; not
nly SSS but also typical symptomatic Brugada syndrome
ith spontaneous VF episode. These apparent discrepancies
n clinical features may suggest the presence of environmen-
al or other genetic factors modifying the phenotypes.
Notably, we found a frame-shift SCN5A mutation
K1578fs/52) in a familial SSS case (K-202). Four family
embers, including the proband, had received a pacemaker
fter being diagnosed with SSS. To assess the association
ith Na channel dysfunction in this SSS case, we carried
ut a pilsicainide provocation test. A low dose of intrave-
ous pilsicainide induced a Brugada-type elevation in ST
nd programmed electrical stimulation-provoked VT. This
ase provides an important insight into the potential overlap
etween SSS and Brugada syndrome. In familial SCN5A-
inked SSS cases, the presence of asymptomatic Brugada
yndrome may have to be taken into consideration.
In summary, our studies showed Brugada plus brady-
rrhythmias (SSS/AVB) type of overlap syndrome was
aused by single SCN5A mutations that result in a complete
oss-of-function in cardiac Na channels. In order to reveal
he cellular and molecular mechanisms by which SCN5A
utations produce a variety of phenotypes, further studies
ill be needed, including the establishment of animal
odels of cardiac Na channelopathies.
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